Hasil Pencarian  ::  Simpan CSV :: Kembali

"At this time there is an increasing demand for an accurate pre operative staging in non small cell lung cancer. Chest Computed Tomography (CT) is one of the imaging modality of choice used for this purpose. This study evaluated the accuracy of the chest CT to determine the status of tumor and nodules in non small cell lung cancer. During the years 1998 and 1999 a descriptive prospective study of 32 patients undergoing a contact enhanced chest CT examination for non small cell lung cancer, stage I-IIIA, was conducted. Lobectomy, lu\ymph nodes dissection and postoperatice histo-pathological examination were done. CT findings were as followas a sensitivity of 100% , a specificity of 25% and an accuracy of 60% in the detection of the nodule stage were found. In 17 patients with adeno-carcinoma, the sensitivity, the specificity and the accuracy were 86.6%, 100% dan 88.2% respectively. The diagnosis of all patients was conformed histo-pathologically. Six patients with T2 dan 26 patients with T3 were detected by chest CT; the accuracy of the tumor status was 93.7% confirmed by surgical and histo-pathological examinations. It was concluded that th CT played an important role in determining the clinical stage of non small cell lung cancer. The specificity and accuracy were higher in adeno-carcinoma as compare with squamous cell carcinoma in detecting the nodal status."

"Latarbelakang: Cell-free DNA (cfDNA) sebagai liquid biopsy dapat digunakan sebagai alat diagnostik noninvasif pada kanker paru. Cell-free DNA membawa informasi genetik sel kanker dan berkorelasi dengan karakteristik tumor. Penelitian ini mengevaluasi perancf DNA dalam menentukan prognosis pada pasien Kanker Paru Bukan Karsinoma Sel Kecil (KPKBSK).Metode: Cell-free DNA diisolasidari 23 serum pasien adenokarsinoma paru di Hiroshima University Hospital pada tahun 2006-2018. Mutasi gen EGFR ekson 19 E745-A750del dan ekson 21 L858R pada tumor diperiksa pada saat diagnosis. Deteksimutasi gen EGFR ekson 19 E745-A750del dan ekson 21 L858R pada cfDNA dilakukan dengan menggunakan droplet digital PCR.Hasil: Dari total 23 pasien, 10 pasien dengan delesi E745-A750del dan 13 pasien dengan mutasi L858R terdeteksi pada tumor. Delesi E745-A750del dan mutasi L858R pada cfDNA terdeteksi pada 6 dan 8 pasien, secara berurutan. Variant allele frekuency yang terdeteksis ebesar 0,01%-18,6%. Median angka tahan hidup untuk pasien yang terdeteksi cfDNA adalah 42 bulan dan pasien yang tidak terdeteksi cfDNA adalah 76 bulan. (p=0,29).Kesimpulan: Terdeteksi nya cfDNA merupakan petanda noninvasif prognosis yang lebihburuk pada pasien KPKBSK.

---

Background: Cell-free DNA (cfDNA) as liquid biopsy can be used as a nonivasive diagnostic tool in lung cancer. Cell-free DNA carries genetic information from cancer cells and correlated with the tumor characteristics. The present study evaluated the role of cfDNA to predict the prognosis in the nonsmall cell lung cancer (NSCLC

Methods: Cell-free DNA were isolated from 23 serum from lung adenocarcinoma patients in Hiroshima University Hospital in 2006-2018. EGFR exon 19 E740-A750 del and exon 21 L858R in the tumor were analyzed at the time of diagnosis. EGFR exon 19 E740-A750 del and exon 21 L858R in cfDNA were detected using droplet digital PCR.

Results: Of 23 patients. 10 patients with E745-A750del and 13 patients with L858R. E745-A750 del and L858R mutations on cfDNA were detected in 6 and 8, respectively. Variant allele frequency detected ranged from 0.01% to 18.6%. Median overall survival in patient with detected cfDNA was 42 months and in patient with no cfDNA detected was 76 months (p=0.29).

Conclusions: Cell-free DNA detected in the serum is a noninvasif biomarker for worse prognosis in NSCLC."

"Latar Belakang : Penelitian perbandingan kesintasan pasien karsinoma paru bukan sel kecil usia lanjut stadium IIIB/IV yang menjalani kemoterapi dan non-kemoterapi sudah pernah diteliti di negara lain sebelumnya, namun penelitian tersebut di Indonesia belum pernah dilakukan. Penelitian-penelitian terdahulu belum banyak yang memperhitungkan faktor perancu seperti komorbiditas, jenis histopatologi, indeks massa tubuh, stadium, usia dan status fungsional dalam meneliti pengaruh kemoterapi terhadap kesintasan karsinoma paru bukan sel kecil usia lanjut.Tujuan : Mengetahui adakah perbedaan kesintasan satu tahun antara pasien kanker paru karsinoma bukan sel kecil usia lanjut stadium IIIB/IV yang menjalani kemoterapi dan non-kemoterapi.Metode : Kohort retrospektif dengan analisis kesintasan terhadap 232 pasien kanker paru karsinoma bukan sel kecil stadium IIIB/IV dan status fungsional ECOG 0-2 yang berobat jalan maupun rawat inap di RS Cipto Mangunkusumo dan RS Kanker Dharmais Januari 2007-April 2013, terbagi menjadi dua kelompok yaitu yang menjalani kemoterapi dan non-kemoterapi. Kurva Kaplan-Meier digunakan untuk mengetahui kesintasan satu tahun masing-masing kelompok. Analisis bivariat menggunakan uji log-rank, analisis multivariat menggunakan cox proportional hazard regression. Besarnya hubungan variabel kemoterapi dengan kesintasan dinyatakan dengan crude HR dan IK 95% serta adjusted HR dan IK 95% setelah dimasukkan variabel perancu.Hasil : Terdapat 232 pasien kanker paru karsinoma bukan sel kecil yang dibagi menjadi dua kelompok yaitu kemoterapi (118 subyek) dan non-kemoterapi (114 subyek). Persentase mortalitas satu tahun adalah 93,9% pada kelompok non-kemoterapi dan 57,6% pada kelompok kemoterapi. Median kesintasan kelompok non-kemoterapi adalah 2 bulan, sedangkan kelompok kemoterapi 9,73 bulan, p<0,001, HR 3,447(IK 95% 2,522-4,711). Analisis bivariat menunjukkan hubungan bermakna antara kemoterapi dengan kesintasan satu tahun. Analisis multivariat menunjukkan stadium adalah perancu kemoterapi terhadap kesintasan.Simpulan : Kesintasan satu tahun pasien kanker paru bukan sel kecil usia lanjut stadium IIIB/IV yang menjalani kemoterapi lebih baik dibandingkan dengan non-kemoterapi.

---

Background : The effects of chemotherapy on survival in elderly with advanced non-small cell lung cancer has been studied in other country before, but in Indonesia this topic hasn?t been studied. The influence of confounding factors such as comorbidity, histopathology, body mass index, functional status, age and stage of cancer were seldom considered in the earlier studies.Objective : To determine whether there?s a difference in one year survival between elderly with advanced non-small cell lung cancer who received chemotherapy and those who received non-chemoterapeutic approaches.Methods : Retrospective cohort design and survival analysis were used to 232 elderly with advanced non-small cell lung cancer (IIIB/IV) and performance status of ECOG 0-2 who visited Cipto Mangunkusumo Hospital and Dharmais Cancer Hospital between January 2007 and April 2013 that divided into 2 groups according to therapy that they received (chemotherapy and non-chemotherapy). Kaplan-Meier curve was used to evaluate the one year survival of each group. Bivariate analysis was conducted using log-rank test, multivariate analysis was conducted using Cox proportional hazard regression. The extend of relation between advancing age and survival was expressed with crude HR with 95% CI and adjusted HR with 95%CI after adjusting for confounders.Results : There were 232 elderly advanced non-small cell lung cancer that divided into two groups ; chemotherapy (118 subjects) and non-chemotherapy (114 subjects). One year mortality percentage were 93,9% and 57,6% to non-chemotherapy and chemotherapy group. The survival median were 2 months in non-chemotherapy group and 9,73 months in chemotherapy group, with p< 0,001 and HR 3,447 (95% CI : 2,522-4,711). Bivariate analysis showed statistically significant relation between chemotherapy and one year survival. Multivariate analysis showed that stage of cancer was a confounder to chemotherapy relation to survival.Conclusion : One year survival in elderly with advanced non-small cell lung cancer who received chemotherapy were better compared to those who received non-chemotherapeutic approaches."

"Latar Belakang: Kanker paru merupakan salah satu jenis keganasan tersering penyebab kematian di dunia. Penelitian faktor-faktor prognostik pada Non-Small Cell Lung Carcinoma sangatlah penting karena berpotensi membawa kita kepada tatalaksana pasien yang lebih baik. CYFRA 21-1 dan CEA merupakan penanda tumor yang diketahui memiliki spesifisitas tinggi terhadap NSCLC dan dapat digunakan dalam memperkirakan prognosis. Meskipun demikian, belum ada studi yang mencari hubungan CYFRA 21-1 dan CEA terhadap kesintasan satu tahun NSCLC stadium lanjut di Indonesia dan saat ini belum ada nilai titik potong CYFRA 21-1 dan CEA yang terstandarisasi sebagai faktor prognostik.Tujuan: Untuk mengetahui hubungan kadar CEA dan CYFRA 21-1 awal dengan kesintasan satu tahun NSCLC stadium lanjut di RSCM dan menentukan titik potong CEA dan CYFRA 21-1 sebagai faktor prognostik.Metodologi: Desain studi ini adalah kohort retrospektif terhadap 111 subjek penelitian dengan NSCLC stadium lanjut berusia >18 tahun yang terdiagnosa dari Januari 2012 hingga Mei 2018 dan telah diperiksakan CEA dan CYFRA 21-1 saat awal terdiagnosis. Karakteristik nilai CEA dan CYFRA 21-1 awal, status performa, jenis histologi, terapi dan stadium didokumentasikan secara lengkap dan diambil dari data Unit Rekam Medik RSUPN Cipto Mangunkusumo. Studi ini menggunakan analisis kesintasan, cox proportional hazards dan log-rank test.Hasil: Area under the curve (AUC) CEA didapatkan kurang dari 50% (AUC = 0,446) dan tidak bermakna, sebaliknya AUC CYFRA 21-1 cukup bermakna dalam analisis kesintasan ini dengan nilai AUC = 0,741 (0,636-0,847) dan p<0,001. Nilai titik potong CEA didapatkan sebesar >21,285 ng/mL, dengan sensitivitas 48,8% dan spesifisitas 48,3%. Sedangkan nilai titik potong CYFRA 21-1 didapatkan sebesar > 10,9 ng/mL dengan sensitivitas 69,5% dan spesifisitas 65,5%. Variabel-variabel yang memenuhi asumsi proportional hazard pada analisis ini adalah CYFRA 21-1, PS, jenis histologi kanker dan terapi. Nilai p>0,05 didapatkan baik pada kurva analisis CEA maupun stadium sehingga hasil tersebut tidak bermakna pada penelitian ini. CYFRA 21-1 >10,9 ng/mL memiliki HR 1,744 (HR = 1,744; p=0,028). PS dengan ECOG 3-4 memiliki HR 2,434 (HR=2,434;p=0,026), NSCLC jenis non-adenokarsinoma memiliki HR 1,929 (HR=1,929;p=0,029), dan kelompok yang tidak dikemoterapi memiliki HR 2,633 (HR=2,633;p=0,015).Kesimpulan: Nilai CEA awal yang tinggi tidak terbukti berhubungan dengan kesintasan satu tahun NSCLC stadium lanjut, sebaliknya nilai CYFRA 21-1 awal yang tinggi terbukti dapat menjadi faktor prognostik yang signifikan terhadap kesintasan satu tahun NSCLC stadium lanjut di RSCM. Nilai titik potong CYFRA 21-1 sebagai faktor prognostik adalah sebesar >10,9 ng/mL.

---

Background: Lung cancer is one of the most common types of malignancy that causes death in the world. Research of prognostic factors in Non-Small Cell Lung Carcinoma is very important because it has the potential to lead us to better patient management going forward. CYFRA 21-1 and CEA are tumor markers that are known to have high specificity to NSCLC and can be used in estimating prognosis. However, there have been no studies looking for the association of CYFRA 21-1 and CEA with one-year survival of advanced stage NSCLC in Indonesia, and there is currently no cut-off value for CYFRA 21-1 and CEA as standardized prognostic factors.

Objective: This study aims to determine the association of initial CEA and CYFRA 21-1 levels with one-year survival NSCLC advanced stage in RSCM and determine the cut-off value of CEA and CYFRA 21-1 as a prognostic factor.

Methodology: The study design was a retrospective cohort of 111 subjects with advanced stage of NSCLC aged > 18 years who were diagnosed from January 2012 to May 2018 and had initial CEA and CYFRA 21-1 value before being treated. Characteristics of the initial CEA and CYFRA 21-1 values, performance status, type of histology, stage of the disease and therapy were fully documented and taken from the Medical Record Unit of Cipto Mangunkusumo General Hospital. This study used survival analysis, cox proportional hazards and log-rank tests.

Results: The CEA’s area under the curve (AUC) was found to be less than 50% (AUC = 0.446) and not significant, whereas AUC of CYFRA 21-1 was quite significant in this survival analysis with AUC = 0.741 (0.636-0.847) and p <0.001. CEA cut-off point were obtained > 21,285 ng / mL, with a sensitivity of 48.8% and specificity of 48.3%. While the CYFRA 21-1 cut point was > 10.9 ng / mL with a sensitivity of 69.5% and a specificity of 65.5%. The variables that meet the proportional hazard assumption in this analysis are CYFRA 21-1, PS, the cancer histology and therapy. A p value > 0.05 was obtained both on the CEA and the stage analysis curve so that the results were not significant in this study. CYFRA 21-1 > 10.9 ng / mL has HR 1,744 (HR = 1,744; p=0,028), PS with ECOG 3-4

had HR 2,434 (HR=2,434; p=0,026), NSCLC non-adenocarcinoma type had HR 1,929 (HR=1,929;p=0,029), and non-chemotherapy group had HR 2,633 (HR=2,633;p=0,015).

Conclusion: A high initial CEA value was not proven to be associated with one-year survival of advanced stage NSCLC, whereas conversely a high initial CYFRA 21-1 value was shown to be a significant prognostic factor for one-year survival of advanced stage NSCLC in RSCM. The cut-off point of CYFRA 21-1 as a prognostic factor is > 10.9 ng

/mL.

"

"Latar Belakang: Usia lanjut dan hubungannya dengan kesintasan kanker paru karsinoma bukan sel kecil sudah diteliti sebelumnya, namun kesintasannya di rumah sakit di Indonesia belum diteliti. Belum banyak penelitian lain yang memperhitungkan faktor perancu antara lain derajat keparahan penyakit, status fungsional, komorbiditas, dan indeks massa tubuh dalam meneliti pengaruh pertambahan usia dengan kesintasan kanker paru karsinoma bukan sel kecil. Tujuan: Mengetahui adakah perbedaan kesintasan satu tahun pasien kanker paru karsinoma bukan sel kecil usia lanjut dan bukan usia lanjut yang diterapi di semua stadium dengan mempertimbangkan functional status, indeks massa tubuh, dan komorbiditas. Metode: Kohort retrospektif dengan pendekatan analisis kesintasan terhadap 227 pasien kanker paru karsinoma bukan sel kecil yang berobat jalan maupun rawat inap di RS Cipto Mangunkusumo dan RS Kanker Dharmais tahun 2002-2012, terbagi 2 kelompok berdasarkan usia saat diagnosis (<60 tahun dan >60 tahun). Kurva Kaplan-Meier digunakan untuk mengetahui kesintasan satu tahun masingmasing kelompok. Analisis bivariat menggunakan uji log-rank, analisis multivariat menggunakan cox proportional hazard regression. Besarnya hubungan variabel usia dengan kesintasan dinyatakan dengan crude HR dan IK 95% serta adjusted HR dan IK 95% setelah dimasukkan variabel perancu. Hasil dan Pembahasan: Terdapat 227 pasien adalah kanker paru karsinoma bukan sel kecil yang diterapi dimana karakteristik kedua kelompok (<60 tahun dan >60 tahun) sebanding kecuali jenis kelamin, merokok, ada tidaknya komorbiditas, dan jumlah komorbiditas. Persentase mortalitas satu tahun adalah 68,0% dan 61,9% untuk kelompok usia <60 dan >60 tahun dengan median kesintasan 8 dan 9 bulan bulan. Analisis bivariat tidak menunjukkan hubungan bermakna antara usia dengan kesintasan satu tahun. Simpulan: Tidak ada pengaruh usia terhadap kesintasan satu tahun pasien kanker paru karsinoma bukan sel kecil yang diterapi di RS Cipto Mangunkusumo dan RS Kanker Dharmais di semua stadium dengan mempertimbangkan functional status, indeks massa tubuh, dan komorbiditas.

---

Background: Old age and its relations to non-small cell lung carcinoma survival has been studied before but its survival in Indonesia has not been studied before. Not many studies that have considered confounders, such as stage, functional status, comorbidities and body mass index, in the study between advancing age and non-small cell lung cancer carcinoma survival.

Aim: To evaluate differences of treated non-small cell lung carcinoma one year survival between non-elderly and elderly considering stages, functional status, body mass index and comorbidities.

Methods: Retrospective cohort design and survival analysis were used to 227 patients with non-small cell lung cancer that being treated at Cipto Mangunkusumo Hospital and Dharmais Cancer Hospital between 2002 and 2012 that divided into 2 groups according to age at diagnosis (<60 years and >60 years). Kaplan-Meier curve was used to evaluate the one year survival of each group. Bivariate analysis was conducted using log-rank test, multivariate analysis was conducted using cox proportional hazard regression. The extend of relation between advancing age and survival was expressed with crude HR with 95% CI and adjusted HR with 95% CI after adjusting for confounders.

Results and Discussion: There were 227 non-small cell lung carcinoma being treated whereas the characteristics between two groups (<60 years and >60 years) were the same except for sex, smoking status, comorbidities and number of comorbidities. One year mortality percentage were 68.0% and 61.9% to <60 years and >60 years groups, respectively, with the survival median of 8 and 9 months. Bivariate analysis didn’t find statistically significant relation between age and one year survival.

Conclusion: Age didn’t influence one year survival of treated non-small cell lung carcinoma at Cipto Mangunkusumo Hospital and Dharmais Cancer Hospital considering stage, functional status, comorbidities and body mass index."

"Kanker paru-paru, khususnya Non-Small Cell Lung Cancer (NSCLC), dapat diberikan perawatan radioterapi baik untuk tujuan kuratif maupun paliatif. Selama radioterapi, perubahan anatomi pasien dapat terjadi, sehingga radioterapi adaptif menjadi sangat penting. Penelitian ini bertujuan untuk mengevaluasi akurasi registrasi citra deformable pada pasien NSCLC dengan menggunakan dua metode yang berbeda: Intermediate Deformable Image Registration (IDIR) sebagai metode registrasi klasik dan VoxelMorph sebagai metode berbasis pembelajaran mesin. Data yang digunakan adalah citra CT dan CBCT dari 17 pasien NSCLC di Siloam Hospital TB Simatupang, Jakarta Selatan. Citra diberi empat label menggunakan model YOLOv9 dan dievaluasi menggunakan metrik Dice Similarity Coefficient (DSC) serta Mean Distance to Agreement (MDA). Metode IDIR dengan rata-rata runtime 198,128 detik, menghasilkan nilai rata-rata DSC macro 0,786 dan micro 0,923. Rata-rata MDA segmentasi 0,166mm dan MDA dengan ambang batas sebesar 7,218mm. Sementara itu, metode VoxelMorph dengan rata-rata runtime 0,735 detik, menghasilkan nilai rata-rata DSC macro 0,635 dan micro 0,987. Rata-rata MDA segmentasi 0,588mm dan MDA dengan ambang batas sebesar 9,634mm. Hasilnya, evaluasi citra hasil registrasi deformable menunjukkan keberhasilan proses registrasi yang dilakukan. IDIR menunjukkan akurasi tinggi dengan runtime cenderung lebih lama, sedangkan VoxelMorph unggul dalam efisiensi runtime dengan penurunan hasil evaluasi.

---

Lung cancer, especially Non-Small Cell Lung Cancer (NSCLC), can be treated with radiotherapy for both curative and palliative purposes. During radiotherapy, anatomical changes in patients may occur, making adaptive radiotherapy crucial. This study aims to evaluate the accuracy of deformable image registration in NSCLC patients using two different methods: Intermediate Deformable Image Registration (IDIR) as a classical registration method and VoxelMorph as a machine learning-based method. The data used consists of CT and CBCT images from 17 NSCLC patients at Siloam Hospital TB Simatupang, South Jakarta. The images were annotated with four labels using the YOLOv9 model and evaluated using Dice Similarity Coefficient (DSC) and Mean Distance to Agreement (MDA) metrics. IDIR method, with an average runtime of 198.128 seconds, yielded average DSC macro values of 0.786 and micro values of 0.923. The average segmentation MDA was 0.166mm, and the boundary MDA was 7.218mm. On the other hand, VoxelMorph method, with an average runtime of 0.735 seconds, produced average DSC macro values of 0.635 and micro values of 0.987. The average segmentation MDA was 0.588mm, and the boundary MDA was 9.634mm. Overall, the evaluation of deformable image registration results indicated successful registration processes. IDIR demonstrated high accuracy with longer runtimes, whereas VoxelMorph excelled in runtime efficiency with slightly lower evaluation results."

"Latar Belakang : Pasien kanker paru sering mengalami pneumonia, hal ini terjadikarena penurunan daya tahan tubuh. Pneumonia menyulitkan penanganan,memperburuk kualitas hidup, mengurangi survival dan seringkali merupakanpenyebab langsung kematian pasien kanker paru. Penangananan pneumonia padapasien NSCLC(non small cell lung cancer) dengan antimikroba yang terus menerustanpa memperhatikan kultur sensisitivitas akan menyebabkan resistensi dari kumanpenyebab pneumonia tersebut.Tujuan : Penelitian ini bertujuan untuk mengetahui, pola kuman penyebabpneumonia pada pasien NSCLC, dan membandingkan kesintasan pasien NSCLCyang menderita pneumonia yang disebabkan oleh bakteri MDR (multidrugresistance) dengan yang disebabkan oleh bakteri non-MDR.Metode : Penelitian ini merupakan kohort retrospektif dengan subjek penelitianadalah pasien NSCLC dengan pneumonia yang disebabkan oleh bakteri MDR dannon-MDR yang dirawat di Rumah Sakit Dr Cipto Mangunkusumo bulan Januari2013-Desember 2017. Analisis dilakukan dengan analisis multivariat regressi cox.Hasil: Setelah dilakukan pemeriksaan kultur BAL(Bronchoalveolar lavage), cairanpleura dan sputum, diperoleh 32 subjek hasil kulturnya hanya bakteri MDR, 14subjek tumbuh bakteri MDR dan non-MDR, dan 23 subjek hanya tumbuh bakterinon-MDR. Bakteri non-MDR terbanyak penyebab pneumonia pada pasienNSCLC adalah Klebsiella pneumoniae sebanyak 37,3%, sedangkan bakteri MDRyang terbanyak menyebabkan pneumonia pada pasien NSCLC adalahAcinetobacter baumannii sebanyak 23,2%. Median survival Pasien NSCLCdengan pneumonia yang disebabkan oleh bakteri MDR adalah 57 hari(43,707-70,293) sedangkan yang oleh bakteri non-MDR 92 hari(58,772-125,228).Simpulan : kesintasan pasien NSCLC dengan pneumonia yang disebabkan olehbakteri MDR lebih singkat daripada yang disebabkan oleh bakteri non-MDR.

---

Back Ground: Lung cancer patients often experience pneumonia. This is due tothe decrease in body endurance of the patients. Pneumonia complicatestreatment, worsens the quality of life, reduces survival and is often a direct causeof death for lung cancer patients. Dealing with pneumonia in non-small cell lungcancer (NSCLC) patients with continuous antimicrobials treatment withoutregard to culture sensitivity will cause resistance of germs that cause pneumonia.Objectives: This study aims to study the pattern of germs that cause pneumoniain NSCLC patients, and to compare the survival of NSCLC patients sufferingfrom pneumonia caused by MDR (multidrug resistance) bacteria with thosecaused by non-MDR bacteria.Methods: This study was a retrospective cohort with research subjects wasNSCLC patients with pneumonia caused by MDR and non-MDR bacteria whowere treated at Dr. Cipto Mangunkusumo Hospital from January 2013 toDecember 2017. Analysis was performed with multivariate cox regressionanalysis.Results: The results of the culture examination of BAL(Bronchoalveolar lavage),pleural fluid and sputum showed that 32 subjects were infected only from MDRbacteria, 14 subjects infected by both MDR and non MDR bacteria, and 23subjects were infected by only non MDR bacteria. The most non-MDR bacteriathat cause pneumonia in NSCLC patients was Klebsiella pneumoniae as much as37,3%, while the most MDR bacteria that cause pneumonia in NSCLC patientswas Acinetobacter baumannii as much as 23,2%. Median survival of NSCLCpatients with pneumonia caused by MDR bacteria was 57 days(43,707-70,293)while those by non-MDR bacteria was 92 days (58,772-125,228).Conclusions: The survival of NSCLC patients with pneumonia caused by MDRbacteria is shorter than that caused by non-MDR bacteria."

"[ABSTRAKPendahuluan. Kanker paru jenis karsinoma bukan sel kecil (KPKBSK) terdiri dari nonskuamosa dan skuamosa. Kanker paru jenis karsinoma bukan sel kecil nonskuamosa adalah adenokarsinoma dan karsinoma sel besar. Saat ini terapi kanker paru sangat berkembang dari agen kemoterapi sampai terapi target terutama EGFR-TKI. Penelitian ini bertujuan untuk menilai angka tahan hidup pasien KPKSBK nonskuamosa yang mendapat kemoterapi lini pertama dibandingkan terapi EGFR-TKI di RSUP Persahabatan.Metode. Penelitian ini adalah penelitian retrospektif antara tahun 2010 sampai 2013 dari rekam medis pasien KPKBSK non skumosa yang mendapatkan kemoterapi lini pertama dan EGFR-TKI. Pasien dikemoterapi dengan platinum baseddan EGFR-TKI diterapi gefitinib 1x250 mg/hari atau erlotinib 1x150 mg/hari. Angka tahan hidup dinilai dari mulai tegak diagnosis sampai pasien meninggal atau saat penelitian dihentikan.Hasil. Dari 96 sampel KPKBSK non skuamosa terdiri dari 48 pasien yang mendapat kemoterapi lini pertama dan 48 pasien yang diterapi EGFR-TKI. Berdasarkan karakteristik pasien, usia terbanyak adalah 40-60 tahun (kemoterapi 32 (66,7%) dan EGFR-TKI 31 (64,6%) dengan jenis kelamin laki-laki yang mendominasi (kemoterapi 25(52,1%), EGFR-TKI 27 (56,2%). Pasien merokok yang mendapat kemoterapi lini pertama 41,7% dan EGFR-TKI 56,3% dengan IB terbanyak untuk kemoterapi (IB ringan 27,1%) dan untuk EGFR-TKI (IB sedang 22,9%). Jenis histologi adenokarsinoma 95,8% dengan dominasi stage IV 89,6% (kemoterapi 91,7% dan EGFR-TKI 87,5%) disertai tampilan status 2 59,4%. Angka tahan hidup pasien (ATH) 6 bulan 74%, ATH 1 tahun 22,90% dan ATH 2 tahun 6,20%. Masa tengah tahan hidup (MTTH) pasien yang mendapat EGFR-TKI lebih lama sedikit dibandingkan yang mendapat kemoterapi lini pertama (263 hari versus 260 hari.Kesimpulan. Masa tahan hidup 1 tahun pasien KPKBSK non skuamosa yang diterapi EGFR-TKI sedikit lebih lama dibandingkan kemoterapi lini pertama (263 hari vs 260 hari). Sedangkan ATH 1 tahun pasien kemoterapi lini pertama lebih besar dibandingkan EGFR-TKI (25% vs 20,8%). Faktor yang paling mempengaruhi angka tahan hidup adalah stage dengan nilai p<0,05.

---

ABSTRACT Introduction. Lung cancer is the type of non-small cell carcinoma (NSCLC) consists of non-squamous and squamous. Non-small cell lung cancer of non squamous types consist of adenocarcinoma and large cell carcinoma. Currently, lung cancer therapy is highly developed of chemotherapeutic agents to targeted therapy especially EGFR-TKI. This study aims to assess the survival rate of NSCLC patients of non-squamous type who receive first line chemotherapy and those who recieve EGFR-TKI therapy at Persahabatan hospital.Methods. This study is a retrospective study between 2010 to 2013 from the medical records of NSCLC patients of non-squmous type who receive first-line chemotherapy and thise who recieve EGFR-TKI.Patients with platinum-based chemotherapy and EGFR-TKI with gefitinib therapy 1x250 mg/day or erlotinib 1x150mg/day. Survival rate assessed from start to erect the diagnosis until the patient dies or when the study is discontinued.Result. From 96 subject of NSCLC patients with non-squamous type consisted of 48 patients who receive first-line chemotherapy, and 48 patients are treate with EGFR-TKI. Based on the characteristics of the patients, most are 40-60 years old (chemotherapy 32 (66.7%) and EGFR-TKI 31 (64.6%) with the male gender that dominates (chemotherapy 25 (52.1%), EGFR-TKI 27 (56.2%). Smoking patients who received first-line chemotherapy are 41.7% and 56.3% of EGFR-TKIs with chemotherapy highest IB (mild IB 27.1%) and for EGFR-TKI (moderate IB are 22.9%). 95.8% of adenocarcinoma histology type with a predominance of stage IV 89.6% (91.7% for chemotherapy and EGFR-TKI 87.5%) with performance status 2 59.4% . Survival rate of patients are 74% for 6 months survival, 1 year survival rate is 22.90% and 2 years survival rate of 6.20%. Median period of survival rate in patients who receiving EGFR-TKI longer than they received first-line chemotherapy (263 days versus 260 days).Conclusion. Median survival rate of non-squamous NSCLC that treated by EGFR-TKI is longer than first-line chemotherapy (263 days vs 260 days). Although 1 year survival rate first-line chemotherapy in patients is greater than EGFR-TKI (25% vs 20.8%). The factors that most influence the survival rate is stages with p value<0.05.;Introduction. Lung cancer is the type of non-small cell carcinoma (NSCLC) consists of non-squamous and squamous. Non-small cell lung cancer of non squamous types consist of adenocarcinoma and large cell carcinoma. Currently, lung cancer therapy is highly developed of chemotherapeutic agents to targeted therapy especially EGFR-TKI. This study aims to assess the survival rate of NSCLC patients of non-squamous type who receive first line chemotherapy and those who recieve EGFR-TKI therapy at Persahabatan hospital.Methods. This study is a retrospective study between 2010 to 2013 from the medical records of NSCLC patients of non-squmous type who receive first-line chemotherapy and thise who recieve EGFR-TKI.Patients with platinum-based chemotherapy and EGFR-TKI with gefitinib therapy 1x250 mg/day or erlotinib 1x150mg/day. Survival rate assessed from start to erect the diagnosis until the patient dies or when the study is discontinued.Result. From 96 subject of NSCLC patients with non-squamous type consisted of 48 patients who receive first-line chemotherapy, and 48 patients are treate with EGFR-TKI. Based on the characteristics of the patients, most are 40-60 years old (chemotherapy 32 (66.7%) and EGFR-TKI 31 (64.6%) with the male gender that dominates (chemotherapy 25 (52.1%), EGFR-TKI 27 (56.2%). Smoking patients who received first-line chemotherapy are 41.7% and 56.3% of EGFR-TKIs with chemotherapy highest IB (mild IB 27.1%) and for EGFR-TKI (moderate IB are 22.9%). 95.8% of adenocarcinoma histology type with a predominance of stage IV 89.6% (91.7% for chemotherapy and EGFR-TKI 87.5%) with performance status 2 59.4% . Survival rate of patients are 74% for 6 months survival, 1 year survival rate is 22.90% and 2 years survival rate of 6.20%. Median period of survival rate in patients who receiving EGFR-TKI longer than they received first-line chemotherapy (263 days versus 260 days).Conclusion. Median survival rate of non-squamous NSCLC that treated by EGFR-TKI is longer than first-line chemotherapy (263 days vs 260 days). Although 1 year survival rate first-line chemotherapy in patients is greater than EGFR-TKI (25% vs 20.8%). The factors that most influence the survival rate is stages with p value<0.05.;Introduction. Lung cancer is the type of non-small cell carcinoma (NSCLC) consists of non-squamous and squamous. Non-small cell lung cancer of non squamous types consist of adenocarcinoma and large cell carcinoma. Currently, lung cancer therapy is highly developed of chemotherapeutic agents to targeted therapy especially EGFR-TKI. This study aims to assess the survival rate of NSCLC patients of non-squamous type who receive first line chemotherapy and those who recieve EGFR-TKI therapy at Persahabatan hospital.Methods. This study is a retrospective study between 2010 to 2013 from the medical records of NSCLC patients of non-squmous type who receive first-line chemotherapy and thise who recieve EGFR-TKI.Patients with platinum-based chemotherapy and EGFR-TKI with gefitinib therapy 1x250 mg/day or erlotinib 1x150mg/day. Survival rate assessed from start to erect the diagnosis until the patient dies or when the study is discontinued.Result. From 96 subject of NSCLC patients with non-squamous type consisted of 48 patients who receive first-line chemotherapy, and 48 patients are treate with EGFR-TKI. Based on the characteristics of the patients, most are 40-60 years old (chemotherapy 32 (66.7%) and EGFR-TKI 31 (64.6%) with the male gender that dominates (chemotherapy 25 (52.1%), EGFR-TKI 27 (56.2%). Smoking patients who received first-line chemotherapy are 41.7% and 56.3% of EGFR-TKIs with chemotherapy highest IB (mild IB 27.1%) and for EGFR-TKI (moderate IB are 22.9%). 95.8% of adenocarcinoma histology type with a predominance of stage IV 89.6% (91.7% for chemotherapy and EGFR-TKI 87.5%) with performance status 2 59.4% . Survival rate of patients are 74% for 6 months survival, 1 year survival rate is 22.90% and 2 years survival rate of 6.20%. Median period of survival rate in patients who receiving EGFR-TKI longer than they received first-line chemotherapy (263 days versus 260 days).Conclusion. Median survival rate of non-squamous NSCLC that treated by EGFR-TKI is longer than first-line chemotherapy (263 days vs 260 days). Although 1 year survival rate first-line chemotherapy in patients is greater than EGFR-TKI (25% vs 20.8%). The factors that most influence the survival rate is stages with p value<0.05.;Introduction. Lung cancer is the type of non-small cell carcinoma (NSCLC) consists of non-squamous and squamous. Non-small cell lung cancer of non squamous types consist of adenocarcinoma and large cell carcinoma. Currently, lung cancer therapy is highly developed of chemotherapeutic agents to targeted therapy especially EGFR-TKI. This study aims to assess the survival rate of NSCLC patients of non-squamous type who receive first line chemotherapy and those who recieve EGFR-TKI therapy at Persahabatan hospital.Methods. This study is a retrospective study between 2010 to 2013 from the medical records of NSCLC patients of non-squmous type who receive first-line chemotherapy and thise who recieve EGFR-TKI.Patients with platinum-based chemotherapy and EGFR-TKI with gefitinib therapy 1x250 mg/day or erlotinib 1x150mg/day. Survival rate assessed from start to erect the diagnosis until the patient dies or when the study is discontinued.Result. From 96 subject of NSCLC patients with non-squamous type consisted of 48 patients who receive first-line chemotherapy, and 48 patients are treate with EGFR-TKI. Based on the characteristics of the patients, most are 40-60 years old (chemotherapy 32 (66.7%) and EGFR-TKI 31 (64.6%) with the male gender that dominates (chemotherapy 25 (52.1%), EGFR-TKI 27 (56.2%). Smoking patients who received first-line chemotherapy are 41.7% and 56.3% of EGFR-TKIs with chemotherapy highest IB (mild IB 27.1%) and for EGFR-TKI (moderate IB are 22.9%). 95.8% of adenocarcinoma histology type with a predominance of stage IV 89.6% (91.7% for chemotherapy and EGFR-TKI 87.5%) with performance status 2 59.4% . Survival rate of patients are 74% for 6 months survival, 1 year survival rate is 22.90% and 2 years survival rate of 6.20%. Median period of survival rate in patients who receiving EGFR-TKI longer than they received first-line chemotherapy (263 days versus 260 days).Conclusion. Median survival rate of non-squamous NSCLC that treated by EGFR-TKI is longer than first-line chemotherapy (263 days vs 260 days). Although 1 year survival rate first-line chemotherapy in patients is greater than EGFR-TKI (25% vs 20.8%). The factors that most influence the survival rate is stages with p value<0.05., Introduction. Lung cancer is the type of non-small cell carcinoma (NSCLC) consists of non-squamous and squamous. Non-small cell lung cancer of non squamous types consist of adenocarcinoma and large cell carcinoma. Currently, lung cancer therapy is highly developed of chemotherapeutic agents to targeted therapy especially EGFR-TKI. This study aims to assess the survival rate of NSCLC patients of non-squamous type who receive first line chemotherapy and those who recieve EGFR-TKI therapy at Persahabatan hospital.Methods. This study is a retrospective study between 2010 to 2013 from the medical records of NSCLC patients of non-squmous type who receive first-line chemotherapy and thise who recieve EGFR-TKI.Patients with platinum-based chemotherapy and EGFR-TKI with gefitinib therapy 1x250 mg/day or erlotinib 1x150mg/day. Survival rate assessed from start to erect the diagnosis until the patient dies or when the study is discontinued.Result. From 96 subject of NSCLC patients with non-squamous type consisted of 48 patients who receive first-line chemotherapy, and 48 patients are treate with EGFR-TKI. Based on the characteristics of the patients, most are 40-60 years old (chemotherapy 32 (66.7%) and EGFR-TKI 31 (64.6%) with the male gender that dominates (chemotherapy 25 (52.1%), EGFR-TKI 27 (56.2%). Smoking patients who received first-line chemotherapy are 41.7% and 56.3% of EGFR-TKIs with chemotherapy highest IB (mild IB 27.1%) and for EGFR-TKI (moderate IB are 22.9%). 95.8% of adenocarcinoma histology type with a predominance of stage IV 89.6% (91.7% for chemotherapy and EGFR-TKI 87.5%) with performance status 2 59.4% . Survival rate of patients are 74% for 6 months survival, 1 year survival rate is 22.90% and 2 years survival rate of 6.20%. Median period of survival rate in patients who receiving EGFR-TKI longer than they received first-line chemotherapy (263 days versus 260 days).Conclusion. Median survival rate of non-squamous NSCLC that treated by EGFR-TKI is longer than first-line chemotherapy (263 days vs 260 days). Although 1 year survival rate first-line chemotherapy in patients is greater than EGFR-TKI (25% vs 20.8%). The factors that most influence the survival rate is stages with p value<0.05.]"

"[Latar belakang : Angka ketahanan hidup dalam 5 tahun pasien penderitakeganasan kanker ovaeium rendah, karena > 70% kasus terlambat didiagnosis.CA125 asites merupakan metode untuk memprediksi kanker ovarium pra bedahsebelum dilakukan tindakan atau tatalaksanha selanjutnya. Tujuan : Penelitian ini bertujuan untuk menurunkan angka kematian akibatkanker ovarium stadium lanjut.Metode : Uji ini adalah uji diagnostik dengan desain potong lintang. Penelitianberlangsung dari Juli 2014 sampai Juni 2015 di Poli onkologi DepartemenObstetri dan Ginekologi RSUPN Dr Cipto Mangunkusumo sampel sebanyak 41kasus. Sampel diambil langsung dari pasien kanker ovarium dengan asites masif.Selanjutnya sampel di analisa nilai sensitivitas dan spesifitasnya. Hasil : Dari 41 orang subjek penelitian didapatkan nilai sensitivitas dan spesifitasyang cukup baik dalam mendiagnosis kanker ovarium, berturut ? turut nialisensitivitas dan spesifitasnya adalah 96% dan 100%. Pemeriksaan kadar CA125asites dapat dipertimbangkan untuk digunakan sebagai salah satu tumor markeruntuk mendiagnosis kanker ovarium dengan asites masif.Kesimpulan : Kadar CA125 asites memiliki nilai sensitivitas dan spesifitas 96% dan 100% untuk mendiagnosa kanker ovarium jenis sel epitel.;Background : Overall five-year survival rate of ovarian cancer is the lowest ofamongst gynecological malignancies, as it diagnosed in late stage diseases.Preoperative CA125 level in ascites fluid is one of the method to guide thesubsequent management. This research aimed to improve ovarian cancer survivalrate.Method :This study was a diagnostic study with cross-sectional review of CA125level in ascites fluid of 41 ovarian malignancy patients in Obstetrics andGynecology Department of RSUPN Dr. Cipto Mangunkusumo to analyze itssensitivity and specificity. Results :This research showed a good sensitivity and specificity of CA125 level,96 % and 100 % respectively. CA125 level in ascites fluid may consider as one ofthe tumour marker to diagnose ovarian malignancy with massive ascited fluid.Conclusion: CA125 level in ascites fluid had a good sensitivity and specificity to diagnose epithelial ovarian malignancy., Background : Overall five-year survival rate of ovarian cancer is the lowest ofamongst gynecological malignancies, as it diagnosed in late stage diseases.Preoperative CA125 level in ascites fluid is one of the method to guide thesubsequent management. This research aimed to improve ovarian cancer survivalrate.Method :This study was a diagnostic study with cross-sectional review of CA125level in ascites fluid of 41 ovarian malignancy patients in Obstetrics andGynecology Department of RSUPN Dr. Cipto Mangunkusumo to analyze itssensitivity and specificity. Results :This research showed a good sensitivity and specificity of CA125 level,96 % and 100 % respectively. CA125 level in ascites fluid may consider as one ofthe tumour marker to diagnose ovarian malignancy with massive ascited fluid.Conclusion: CA125 level in ascites fluid had a good sensitivity and specificity to diagnose epithelial ovarian malignancy.]"

"Peningkatan kasus kanker yang terjadi setiap tahun, termasuk pada kanker serViks menjadi penyebab utama kedua kematian akibat kanker pada perempuan di seluruh dunia. Kenaikan kasus tersebut juga diikuti dengan perkembangan penanganan dan pengobatan kanker. Obat alternatif yang bersifat nontoksik, lebih terjangkau, dan aman dengan efektiVitas yang lebih tinggi daripada pengobatan konVensional kanker yang berkembang saat ini terus dicari. Salah satunya menggunakan tanaman obat akar wangi (Chrysophogon zizanioides (L.) Roberty). Penelitian ini dilakukan untuk menganalisis pengaruh Variasi konsentrasi ekstrak akar wangi yang diekstraksi dengan metode maserasi. Pengaruh ekstrak akar wangi dengan Variasi konsentrasi 5, 10, 15 dan 20 μg/mL diuji terhadap Viabilitas sel HeLa dengan metode analisis WST-1 dan scepter cell counter. Hasil uji statistik pada tingkat kepercayaan 0,05 menunjukkan bahwa tidak terdapat perbedaan signifikan nilai Viabilitas, nilai konsentrasi, diameter dan Volume sel antara sampel kontrol dan perlakuan. Namun, ekstrak akar wangi dengan konsentrasi 15 μg/mL diketahui cenderung lebih mampu menurunkan Viabilitas sel HeLa jika dibandingkan dengan konsentrasi akar wangi lainnya.

---

The increase in cancer cases that occur every year, including cervical cancer, is the second leading cause of cancer death in women worldwide. The increase in cases was also followed by the development of cancer treatment and treatment. Alternative drugs that are nontoxic, more affordable, and safe with higher effectiveness than conventional cancer treatments are currently being sought. One of them uses a medicinal plant vetiver (Chrysophogon zizanioides (L.) Roberty). This study was conducted to analyze the effect of variations in the concentration of vetiver extract extracted by the maceration method. The effect of vetiver extract with various concentrations of 5, 10, 15 and 20 g/mL was tested on the viability of HeLa cells using WST-1 and scepter cell counter analysis methods. The results of statistical tests at a confidence level of 0.05 showed that there was no significant difference in the value of viability, concentration value, diameter and volume between the control and treatment samples. However, vetiver extract with a concentration of 15 g/mL tended to be more able to reduce HeLa cell viability when compared to other vetiver concentrations."